Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: I posted a question last week to the board experts. I did not receive a reply :

I hate to say it but that is a rather bush-league question.  Comparing our o/s with any other company’s o/s is essentially meaningless – apples and oranges.  Without simultaneously factoring in earnings, o/s have little meaning, as least comparatively speaking.  There is zero correlation between our o/s and J2 o/s. 

 

O/S are the denominator in the eps calculation.  The greater the denominator, the lower the eps.  Assume $100 million in profit and figure out our eps; then re-figure it pretending that we only had 50 million shares outstanding  --- waalaaa.  That is why you hear the board talk about our o/s; it has nothing to do with J2 o/s.  Many here simply wish we had not had to issue so many shares or equivalents over the years to stay alive; otherwise our eps would look a lot better, and ultimately p/e ratio. 

Share
New Message
Please login to post a reply